Population Health
DeepHealth Lung
AI-powered nodule detection, reporting, and patient management for enhanced efficiency and accuracy in lung cancer diagnosis
DeepHealth Lung is an AI-powered solution designed to enhance lung cancer diagnosis and reporting. It integrates seamlessly into existing Picture Archiving and Communication Systems (PACS), offering both onsite and cloud deployment options to minimize workflow disruptions. Trained on over 40,000 scans, DeepHealth Lung automates the detection, classification, quantification, and growth assessment of pulmonary nodules, identifying solid and sub-solid nodules ranging from 3 to 30mm with 95% sensitivity and no more than two false positives per scan.
The system provides accurate measurements of nodule diameters and volumes, and can automatically retrieve prior scans to calculate growth percentage and volume doubling time. Widely adopted across nearly 100 locations in the UK and EU, including 41 out of 45 sites in the UK’s Targeted Lung Health Checks program, DeepHealth Lung processes over 50,000 scans monthly, delivering standardized, customizable, and shareable lung nodule reports to support efficient clinical workflows.
Seamless workflow integration
3 to 30 mm growth
Vendor agnostic
Direct PACS integration
Remote accessibility
Beyond The Diagnosis: Transforming Cancer Care Through Innovation
Find out how those who live with and work with cancer are rewriting the narrative in a brand-new digital series presented by Union for International Cancer Control and produced for them by BBC StoryWorks Commercial Productions.
The series explores innovative solutions for cancer prevention, diagnosis, treatment and care, and spotlights DeepHealth’s role in transforming lung cancer screening.
Learn more
British Society of Urogenital Radiology (BSUR) Annual Scientific Meeting
How cloud computing is helping bring AI to hospitals worldwide
RadNet’s DeepHealth Subsidiary Expands FDA Clearance for SmartMammo™ Solution
Somerville, MA, November 29, 2024 – DeepHealth, Inc., a wholly-owned subsidiary of RadNet, Inc. (NASDAQ: RDNT) and a global leader in AI-powered health informatics, has received expanded FDA 510(k) clearance for its innovative mammography software. SmartMammo Dx, the AI algorithm within SmartMammo1, is now FDA-cleared to be compatible with GE HealthCare’s Senographe Pristina™ mammography systems.